Cancer Immunotherapy Conference features latest research on response, resistance, treatment

September 30, 2018

NEW YORK -- The Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, to be held in New York, Sept. 30-Oct. 3, will feature cutting-edge research studies from around the world that endeavor to answer urgent questions in the field of cancer immunotherapy to advance progress more rapidly for patients.

Cancer immunotherapeutics work by unleashing the power of a patient's immune system to fight cancer the way it fights pathogens like viruses and bacteria. Immune checkpoint inhibitors such as pembrolizumab and nivolumab, as well as CAR T-cell therapy, have revolutionized cancer care in recent years by yielding dramatic, durable responses in patients who previously had few treatment options. However, such responses are seen in only a fraction of patients, and many patients develop resistance to these treatments. There is a need for continued research and innovation so that more patients may benefit from the promise of cancer immunotherapy.

"We have made extraordinary progress in cancer immunotherapy in the past decade -- the number of immunotherapeutics increased almost five-fold and the number of cancer types that can be treated by at least one immunotherapeutic more than tripled," said AACR President Elizabeth M. Jaffee, MD, co-chair of this year's conference and deputy director of The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University. "As research expands our knowledge of the immune system and how it interacts with cancer cells, we will see a lot more progress in immunotherapy, with new approaches to treatment that will increase the number of patients who benefit."

A media luncheon will take place on Monday, Oct. 1, at 1 p.m. ET featuring cancer immunotherapy experts who will discuss these areas of research interest and other themes from the meeting. Reporters interested in attending remotely can watch live at https://youtu.be/9G_ufP3LEjg.

Several presentations at the conference also address these issues.

Who responds to immune checkpoint inhibitors, and why?

Developing new approaches in identifying responders and non-responders to immune checkpoint inhibitors can help determine who should receive these drugs and who should receive alternate treatment.

One study that utilized big data and genomic analysis to identify new patients who may respond to immune checkpoint inhibitors is Abstract B085, "High mutation burden and response to immune checkpoint inhibitors in angiosarcomas of the scalp and face," to be presented by Corrie Painter, PhD, from the Broad Institute of MIT and Harvard during Poster Session B on Tuesday, Oct. 2.

What can be done to improve response rates and overcome resistance to immune checkpoint inhibitors?

Immune checkpoint inhibitors improve outcomes for only a subset of cancer patients, and many see their cancers stop responding to treatment. The following abstracts are examples of work that is being done to address these issues:

-Roberta Zappasodi, PhD, Memorial Sloan Kettering Cancer Center, will present Abstract A225/PR1, "Mechanistic rationale to combine GITR agonism with PD-1 blockade in cancer patients," during Poster Session A and Session 1: Regulating T Cells and Their Response to Cancer on Sunday, Sept. 30. This study investigates a new combination treatment that may help counteract resistance.

-Elizabeth Evans, PhD, Vaccinex, Inc., will present Abstract A068/PR10, "Reprogramming myeloid cells in TME with pepinemab, first-in-class semaphorin 4D MAb, enhances combination immunotherapy," during Poster Session A on Sunday, Sept. 30 and Session 5: Novel Vaccine Platforms and Combinations on Tuesday, Oct. 2. This pre-clinical research evaluates the mechanisms behind a new therapeutic's ability to bolster the activity of immune checkpoint inhibitors as these combinations are being investigated in several clinical trials.

-Stephen Schoenberger, PhD, La Jolla Institute for Allergy and Immunology, will present Abstract B090/PR12, "Functional identification and therapeutic targeting of tumor neoantigens," during Poster Session B and Session 6: Mutational Analysis and Predicting Response to Immunotherapy on Tuesday, Oct. 2. The technology described in this study may eventually help identify a broader array of tumor-specific neoantigens, which is important for the development of personalized cancer vaccines and cellular immunotherapies.

In addition, this year's recipient of the William B. Coley Award for Distinguished Research in Tumor Immunology, Padmanee Sharma, MD, PhD, The University of Texas MD Anderson Cancer Center, will deliver a lecture titled "From the clinic to the lab: Investigating response and resistance mechanisms to immune checkpoint therapy," Sunday, Sept. 30, at 2:15 p.m. ET.

What novel immunotherapies are on the horizon for cancer patients?

Besides immune checkpoint inhibitors and CAR T-cell therapy, researchers are investigating other ways to unleash the immune system against cancer. These two abstracts are examples of new approaches to cancer immunotherapy that are being tested in early-phase clinical trials:

-Jay Berzofsky, MD, PhD, Vaccine Branch, Center for Cancer Research, National Cancer Institute, will present Abstract A004, "HER2 cancer vaccine phase I clinical trial shows clinical benefit in 54% of evaluable patients," during Poster Session A on Sunday, Sept. 30. According to these trial results, treatment with a HER2-targeted therapeutic cancer vaccine provided clinical benefit to several patients with metastatic HER2-positive cancers who had not previously been treated with a HER2-targeted therapeutic.

-Filip Janku, MD, PhD, The University of Texas MD Anderson Cancer Center, will present Abstract A011, "First-in-man clinical trial of intratumoral injection of Clostridium novyi-NT spores in patients with treatment-refractory advanced solid tumors: safety, activity, and immune responses," during Poster Session A on Sunday, Sept. 30. This trial demonstrated that the use of bacterial Clostridium novyi-NT spores as an injectable monotherapy had manageable toxicities and showed early clinical efficacy in patients with treatment-refractory solid tumor malignancies.

The scientific program will feature talks from more than 50 leaders in the field, and attract more than 1,200 attendees from academia, industry, and the advocacy community. A full program is available here: http://www.cancerimmunotherapyconference.org/program-of-events/. All abstracts are available through the conference app: http://www.cancerimmunotherapyconference.org/abstracts/.
-end-


American Association for Cancer Research

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.